Article
Author(s):
Polycystic ovary syndrome (PCOS) is one of the most common reproductive endocrine and metabolic diseases in women of childbearing age, but data that compare outcomes between obese and nonobese patients are scarce—something this study sought to remedy.
A new study from China has concluded that to improve outcomes among women with polycystic ovary syndrome (PCOS), reducing the incidence of obesity and insulin resistance may have positive effects on women with the condition. Findings of a comparison between obese and nonobese patients with PCOS appeared in a recent issue of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.
“More than half of PCOS patients are complicated with obesity, and women with PCOS have an increased risk of developing metabolic syndrome over the course of their lives,” the authors wrote. “There are few studies on the metabolism of non-obese PCOS patients, however.”
Their primary outcome was to uncover in-common factors that have an impact on the pathogenesis and progression of PCOS on which to base treatment plans for these individuals.
The 179 patients in the study, from the outpatient clinic of the Shengjing Hospital of the China Medical University, were selected for inclusion from April 2018 to October 2019 and divided into 4 groups, based on body mass index (BMI) and PCOS status:
Overall, in the obese PCOS group, the mean (SD) BMI was almost 40% higher vs the normal BMI PCOS group (30.55 [4.03] vs 21.99 [3.59] kg/m2), the waist-to-hip ratio (WHR) was 12% higher (0.94 [0.06] vs 0.84 [0.04]), and visceral fat area was close to double (149.53 [41.52] vs 75.63 [23.14]). Similar findings were seen between the obese non-PCOS and normal BMI non-PCOS groups, with those classified as obese having higher numbers in the 3 measurements.
These differences were considered statistically significant.
The investigators analysis also found the following:
The authors note their findings show endocrine metabolic disorders were more obvious in the women with PCOS vs those without, despite matching based on BMI; that abnormal glucose and lipid metabolism can have more serious implication among obese PCOS patients vs normal-weight PCOS patients; hyperinsulinemia affected both PCOS patient groups; and that the development and pathogenesis of PCOS may be influenced by insulin resistance.
“Therefore, reducing obesity and insulin resistance are important measures for the treatment of PCOS,” they concluded.
Reference
Shi W, Zhao Q, Zhao X, Xing C, He B. Analysis of endocrine and metabolic indexes in non-obese patients with polycystic ovary syndrome and its compare with obese patients. Diabetes Metab Syndr Obes. 2021;14:4275-4281. doi:10.2147/DMSO.S329108
Ketogenic Diet Shows Promise as Nonpharmacologic Treatment for PCOS
Ketogenic Diet Shows Promise as Nonpharmacologic Treatment for PCOS
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.